Here is a number that should stop you cold the next time you sit across from a patient with schizophrenia, bipolar disorder, or major depression: people living with serious mental illness smoke at roughly two to three times the rate of the general population, and they consume a disproportionate share of all the cigarettes sold in this country. They also die, on average, years earlier than everyone else — and it is not the psychiatric illness that usually kills them. It is the smoking. Heart disease. COPD. Cancer. The slow stuff we tend to file under “someone else’s specialty.”
So why does psychiatry, the specialty that sees these patients more than anyone, so often leave the single most effective quit-smoking medication sitting untouched on the shelf?
The answer is a story about fear, a boxed warning, and one of the largest psychiatric medication trials ever run. If you are studying to become a PMHNP, varenicline deserves a permanent spot in your mental toolkit — not just because it shows up on boards, but because the reasoning behind it is exactly the kind of evidence-versus-instinct conflict you will navigate for the rest of your career.
The drug nobody wanted to prescribe
Varenicline — you may still hear it called by its old brand name, Chantix — is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor. That mechanism is worth memorizing because it explains everything the drug does. As a partial agonist, varenicline gently stimulates the same receptor nicotine hits, which blunts cravings and withdrawal. But because it occupies that receptor, it also blocks nicotine from binding fully — so if a patient lights up while taking it, the cigarette delivers far less of its reward. It takes the floor out from under both the craving and the payoff. That dual action is why it consistently outperforms the alternatives.
And yet, for the better part of a decade, a lot of excellent clinicians wouldn’t touch it.
The reason was a boxed warning — the FDA’s most serious label warning — added in 2009 over reports of depression, agitation, suicidal thoughts, and behavioral changes in people taking varenicline. The signal was real enough to scare prescribers, especially in psychiatry, where our patients already carry elevated baseline risk for exactly those symptoms. Dr. Chris Aiken and Kellie Newsome, PMHNP, captured the chilling effect perfectly in The Carlat Psychiatry Report, describing how a primary care doctor was so spooked by the warning that he phoned a patient with a remote history of depression every single day to screen for suicidal thoughts after starting the drug. As Carlat put it, that warning “probably caused a whole generation of physicians to shy away from varenicline in psychiatric patients — which is a shame, because psychiatric patients are much more likely to smoke and have a much harder time quitting.”
Read that twice. The patients who most needed the best medication were the exact patients we were most afraid to give it to. That is the kind of clinical paradox that should make your ears perk up, because resolving it requires real data — not a hunch, not a vibe, not “better safe than sorry.”

EAGLES: the trial that changed the conversation
The data arrived in 2016, and it was enormous. The EAGLES trial — published in The Lancet by Anthenelli and colleagues — enrolled more than 8,000 smokers across 16 countries and did something unusual and brilliant: it deliberately split the group roughly in half between people with a stable psychiatric disorder (depression, anxiety, bipolar, schizophrenia, and more) and people without one. Then it randomized everyone to varenicline, bupropion, the nicotine patch, or placebo, all paired with counseling.
This design is the whole point. Earlier safety worries came from spontaneous reports and observational data, which can’t separate the drug’s effect from the simple fact that smokers — and people who are trying to quit — carry higher rates of psychiatric symptoms to begin with. EAGLES was built to answer the question cleanly: does varenicline actually cause serious neuropsychiatric harm, and does it work?
On safety, the verdict was reassuring. There was no significant increase in serious neuropsychiatric adverse events attributable to varenicline compared with placebo or nicotine patch — and that held true even in the cohort with psychiatric disorders. Patients on varenicline were no more likely to land in the hospital for psychiatric reasons than patients on nicotine replacement. On the strength of that evidence, the FDA removed the boxed neuropsychiatric warning from varenicline’s label in December 2016.
On efficacy, varenicline didn’t just hold its own — it won, and it won decisively. It beat bupropion, the nicotine patch, and placebo for helping people quit, in both the psychiatric and non-psychiatric groups. A later analysis of the depressed smokers in that dataset, highlighted by Carlat, found varenicline roughly 65% more effective than bupropion or nicotine replacement. Framed another way: patients were about twice as likely to quit with bupropion or the patch, but roughly three-and-a-half times as likely to quit with varenicline. Same disease, same counseling, dramatically different odds — driven entirely by which medication landed in the prescription.
Why this is a 2026 topic, not just a history lesson
You might be thinking: if EAGLES settled this in 2016, why are we still talking about it? Because the field is, only now, finally acting on it — and old habits die hard.
In February 2025, the American Journal of Psychiatry published a commentary by Weinberger and Steinberg arguing for varenicline as a genuine first-line treatment for people with current major depressive disorder who smoke. Not a last resort. Not “only if the patient is psychiatrically rock-solid first.” First-line. That framing matters because it inverts the old reflex. For years the unspoken rule was to stabilize the mood, then maybe, cautiously, address the smoking. The emerging evidence says you can treat the smoking now, even in active depression, with the most effective agent we have — and doing so doesn’t destabilize patients. Major guidelines, including the WHO’s tobacco cessation guidance, list varenicline, bupropion, and nicotine replacement as first-line options, but the head-to-head data keep pointing to varenicline as the strongest of the three.
For a PMHNP student, this is the living edge of practice: a place where the textbook caution and the current evidence point in opposite directions, and where you will have to know the literature well enough to do the harder, better thing.

What you actually need to know to use it
Boards love varenicline because there is a lot to test. Here is the practical core.
Mechanism: alpha-4 beta-2 nicotinic acetylcholine receptor partial agonist. If a question stem describes a smoking-cessation aid that both reduces cravings and blunts the reward of smoking, that is varenicline.
Dosing and timing: varenicline is titrated over the first week to reduce nausea — typically 0.5 mg once daily for three days, then 0.5 mg twice daily for four days, then 1 mg twice daily for maintenance. The classic approach sets a quit date about a week into treatment, though flexible quit-date strategies are also used. Counsel patients to take each dose with food and a full glass of water. A standard course runs about 12 weeks, with an option to extend another 12 weeks to lock in abstinence.
Side effects: nausea is far and away the most common — it affects a sizable minority of patients and is the leading reason people stop the drug. Vivid, strange, sometimes unsettling dreams and insomnia are also common; taking the evening dose with dinner rather than at bedtime can help. Because varenicline is renally cleared, you’ll need to reduce the dose in significant renal impairment.
The safety conversation: the boxed warning is gone, but good practice didn’t disappear with it. You still counsel patients and families to watch for new or worsening mood symptoms, agitation, or unusual behavior, and you still document that conversation. The lesson of EAGLES isn’t “stop monitoring.” It’s “don’t let an outdated fear talk you out of the best treatment.” Those are very different things, and the distinction is exactly what separates a reflexive prescriber from a thoughtful one.
One footnote worth knowing: varenicline was briefly pulled from the market in 2021 when batches of the brand-name product were found contaminated with a nitrosamine impurity. It has since returned and is widely available as a generic, which has also made it far more affordable than it used to be — a real factor for the low-income patients who are overrepresented among smokers with serious mental illness.
The bigger lesson hiding inside a smoking-cessation drug
Here’s why I want you to care about this beyond the exam. Varenicline is a case study in something you will face constantly as a PMHNP: the gap between what the evidence shows and what the culture of a field is comfortable doing. For a decade, fear — understandable, well-intentioned fear — kept an effective, life-extending medication away from the people who needed it most. It took a trial of 8,000 patients to give clinicians permission to do what the science already supported.
Your patients with mental illness are not dying primarily from their psychiatric diagnoses. They are dying from tobacco, and from a healthcare system that too often treats their physical health as someone else’s job. When you become the clinician who asks about smoking, who knows the data cold, and who is willing to reach for the most effective tool instead of the most comfortable one, you are quite literally adding years to people’s lives. That is not a side quest from psychiatric care. That is psychiatric care.
So learn the mechanism. Learn the EAGLES story. Learn the dosing. And then carry the deeper lesson with you: be the kind of PMHNP who lets good evidence — not old fear — guide the prescription pad.
If posts like this are how you want to study — real clinical reasoning, current research, and board-relevant pharmacology you’ll actually remember — come build your prep with us at PMHNPReview.org. Your future patients are counting on the clinician you’re becoming.
